- Novo Nordisk shares tumble as data on weight-loss drug trial disappoints Financial Times
- Novo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints Fortune
- Novo’s CagriSema Obesity Shot Shortfall Shows Danger of Promising Too Much Bloomberg
- Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps CNBC
- Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it CNN
Source: US